MACOM Technology Solutions R&D increased by 3.8% to $68.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.3%, from $57.84M to $68.98M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 15.2% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.62M | $33.61M | $33.68M | $35.47M | $35.46M | $37.63M | $39.68M | $38.83M | $35.54M | $36.67M | $37.51M | $39.41M | $45.62M | $47.53M | $49.59M | $60.37M | $57.84M | $63.38M | $62.88M | $66.46M | $68.98M |
| QoQ Change | — | -2.9% | +0.2% | +5.3% | -0.0% | +6.1% | +5.5% | -2.1% | -8.5% | +3.2% | +2.3% | +5.1% | +15.8% | +4.2% | +4.3% | +21.7% | -4.2% | +9.6% | -0.8% | +5.7% | +3.8% |
| YoY Change | — | — | — | — | +2.4% | +11.9% | +17.8% | +9.5% | +0.2% | -2.5% | -5.5% | +1.5% | +28.4% | +29.6% | +32.2% | +53.2% | +26.8% | +33.3% | +26.8% | +10.1% | +19.3% |